Novel targeted therapies and immunotherapy for advanced thyroid cancers
Abstract Thyroid cancer is a frequently encountered endocrine malignancy. Despite the favorable prognosis of this disease, 15–20% of differentiated thyroid cancer (DTC) cases and most anaplastic types, remain resistant to standard treatment options, including radioactive iodine (RAI). In addition, a...
Main Authors: | George E. Naoum, Michael Morkos, Brian Kim, Waleed Arafat |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-02-01
|
Series: | Molecular Cancer |
Online Access: | http://link.springer.com/article/10.1186/s12943-018-0786-0 |
Similar Items
-
Dawn of Advanced Thyroid Cancer Therapy: Targeted Therapy and Immunotherapy
by: LIU Shanting, et al.
Published: (2023-01-01) -
Advances in targeted therapy and immunotherapy for esophageal cancer
by: Haiou Yang, et al.
Published: (2023-08-01) -
Editorial: Targeted therapy in advanced thyroid cancer
by: Laura Boucai
Published: (2022-09-01) -
Advances in targeted therapy and biomarker research in thyroid cancer
by: Mei Guo, et al.
Published: (2024-03-01) -
Advances in Biomarker-Driven Targeted Therapies in Thyroid Cancer
by: Prachi Mishra, et al.
Published: (2021-12-01)